“The current funding round is expected to be Around $ 250-300 Million,” One of the people cited above said. The company is likely to go public over the next 12-18 months, the second person added.
“The (Valuation) Ask is Around 65,000 Crore, which is more than 40 times its ebitda, “The third person said, adding the company reported an earnings before interest, tax, deprecation and amortization or arbitda of Around 1,300 Crore in FY25. All three people spoke on the condition of anonymity.
Temasek, Adia, and Warburg Pincus Declined to comment on Mint’s Queries, while a Response from Micro Life was unavailableble Until Until Press Time.
The vapi, gujarat-based bilakhia family founded micro life science in 2006. The company has multiple subsidies, with the most prominent being meril life sciences. The bilakhia group, founded by gafurbhai bilakhia, is now managed by his three sons, yunus bilakhia, jakir bilakhia and anjum bilakhia. The company operates in healthcare, investment and real estate through its subsidiaies.
Individually evaluating
“Investments Firms are individually evaluating, and bids are likely to go in next month,” The third person added.
At a Valuation of 65,000 Crore, Warburg Pincus, which investment $ 210 million in Micro Life Three Years ago At a Valuation of Over $ 1.8 billion, may be sitting on a fourfold gains.
“At that value, only a sovereign fund or a state-backed investor can do a deal, given their cost of capital is low,” The third person said.
Meril, A Key Subsidiya of Micro Life, Makes Coronary Stents, Peripheral Stents, Ballon Catheters, and Heart Valves. Micro Life Sciences Reported a Total Income of 3,495 Crore in FY24, Against 2,359 Crore in FY23, According to a Care Ratings report Dated 8 October, 2024. It reported a profit after tax of 333 Crore in FY24, Against 505 Crore in FY23. Profit in Fy23 Included a “Fair Value Gain of 298 Crore from the derecognition of JV Investment, ‘Care Rating Said.
“In terms of sales mix, in fy24, micro earned ~ 40% of its revionue from Cardiac implants (Major Products: Stents, Ballon and Heart Valves), 40% from Orthopaedic Implants Implants, hip implants, and surgical robots) and 10% Each from the diagnostic segment and the surgical segment (Major Products: Sutures and Mechanical Closures), “The note said.
The report added that in some segments, the company Saw “Stable to marginally higher sales realization”, lead to better gross margins. Micro’s Gross Margins Improved to 72.80% in FY24 from 64.64% in FY23 on Better Product Mix.
Arms in 25 Countries
The Micro Group has subsidiaies in more than 25 Countries Including Germany, Turkey, The Us, Russia, South Africa, Brazil, Bangladesh, Australia, China, and the UK. The company sells its products in over 100 countries directly and through its oversas subsidiaies, with expenses realization before
The Indian Medtech Ecosystem has Seen Treamed Investor Interest in Recent Years. In 2024, kkr won a bidding war to acquire healthium from apax partners, while warburg pincus investing over $ 300 million in Appaswamy Associates. Morgan Stanley Private Equity Asia Invested 1,000 Crore in Maiva Pharma, an Injectables Maker.